Halozyme Therapeutics (HALO) Tops Q1 EPS by 8c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $107.06 -2.07%
Financial Fact:
Net income (loss): -28.95M
Today's EPS Names:
EGRX, VAXX, AFIB, More
Financial Fact:
Net income (loss): -28.95M
Today's EPS Names:
EGRX, VAXX, AFIB, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q1 EPS of $0.47, $0.08 better than the analyst estimate of $0.39. Revenue for the quarter came in at $162.14 million versus the consensus estimate of $180.51 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CrowdStrike shares jump on earnings beat, raised outlook
- Agilent Technologies (A) Tops Q3 EPS by 13c, Beats on Revenue; Offers FY EPS Guidance
- CrowdStrike Holdings Inc. (CRWD) Tops Q2 EPS by 2c, Beats on Revenue; Offers FY Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
